Abstract
Introduction
More than a decade ago, the antimalarial drug primaquine was reported to be heavily contaminated with the isomer quinocide, which is much more toxic than primaquine [3] . Today, quinocide is not in use, even in its country of origin, because of its toxicity. Both primaquine and quinocide are antimalarial agents, and are isomers. In tablets, there are four different substances: two stereoisomers of primaquine and two stereoisomers of quinocide. These substances have different toxic, pathological and pharmacological effects on animals and humans [4] - [6] . In 2004, qualitative and quantitative information about primaquine tablets as mixtures of four individual substances and the influence of the contaminant quinocide on the overall toxicological effects of the drugs in these tablets was published [7] . More than 500 million people take these tablets as curative medicine every year. It is a very profitable business for the pharmaceutical industry to produce this medicine from cheap, contaminated raw ware primaquine. Revelation of the contamination of this drug with more toxic substances was and is being ignored by the pharmaceutical industry. Initially, authorities and the pharmaceutical industry suppressed all information about contamination of this drug [8] . This allowed the pharmaceutical industry to sell stockpiles of tablets highly contaminated by quinocide. The contamination level allowed by pharmacopoeias was 6% [9] [10], but in reality it was significantly higher [11] . Despite all attempts of pharmaceutical authorities to ignore the presence in primaquine of alien toxic substances and all efforts to prevent dissemination of knowledge about this, the latest published pharmacopoeias were compelled to acknowledge the force of facts and require a reduction of the presence of quinocide under the definition of "related substances" to 3% [12]- [16] . All these pharmacopoeias avoided naming the alien toxic contaminant as quinocide directly; instead, the contaminant was named as "related substances". After the old tablet stockpiles were consumed, the level of allowed contamination with "related substances" was reduced in pharmacopoeias to 1.5%.
Several methods for determination of the toxic contaminant quinocide in raw ware primaquine and tablets have been published: [17] [18] by using GC-MS in 2004-2005, [19] - [21] by using HPLC and HPLC-MS in 2005, [22] - [24] by using SFC-MS in 2007-2009, and by using gas chromatography-mass spectrometry with supersonic molecular beams (SMB) in 2009 [25] . The biological consequences of primaquine contamination with quinocide were presented in 2011 [26] . All this information was presented over a significant period of time at international meetings, and in technical and scientific international journals and could not be missed by any serious scientist. In Biomedical Chromatography, Elbashir et al. published a paper [27] "Determination of Quinocide as Impurity in Primaquine Tablets by Capillary Zone Electrophoresis"; they also mentioned some of the previous publications that described quinocide analyses in primaquine. All this pointed to the good knowledge about the presence of quinocide in primaquine by Elbashir et al. Primaquine and quinocide are isomers. They have similar molecular formulas and similar UV spectra [8] and undergo the same chemical reactions and by derivatization give isomeric products with similar UV spectra.
Unstoppable Fraud
As mentioned above, primaquine and quinocide are isomers and have similar natures and similar reactions under derivatization and their derivatives have similar UV spectra. The presence of quinocide in primaquine was well known to Elbashir et al. [27] . Despite this, Elbashir et al. [28] published "Spectrophotometric Method for Determination of Primaquine in Pharmaceutical Formulations via Derivatization with 1, 2-Naphthoquinone-4-Sulfonate" by Aida Makram Nouralla Altigani, Abdalla Ahmed Elbashir in Austin Journal of Analytical and Pharmaceutical Chemistry. Nothing was mentioned in this paper about interfering factors or interfering substances, or about the interference of quinocide in the analytical procedures. This paper does not mention the presence of quinocide in primaquine and its reaction with 1, 2-naphthoquinone-4-sulfonate, or that the UV spectrum of the product of derivatization is an interfering factor. This publication is a shameful fraud, but it is not the first fraud published by Elbashir et al. His series of shameful fraudulent publications were criticized in [29] . In connection with publication [27] , the corrupt nature of acceptance for publication of this paper was discussed in [29] . The Editor in Chief of Current Chromatography, Pavel N. Nesterenko, was contacted (Figure 1 ) to give his evaluation of the disclosure presented in [29] . The Associate Editor of Current Chromatography, H. Y. Aboul-Enein (National Research Centre, Cairo, Egypt) was the corresponding author of fraudulent publication. An explanation of his role in the corrupt acceptance for publication of paper was requested.
The following answer was received (Figure 2) . Response to Mr. Nesterenko is shown in Figure 3 . After one month there was no answer from Mr. Nesterenko, the same situation is current despite my subsequent letter to Mr. Nesterenko (Figure 4) 
What Was Wrong?
What was wrong in paper [28] and several other papers that used spectrophotometric techniques? Before presentation [3] and the following series of papers [7] [8] [17] - [26] , the publication of papers such as [30] - [35] were partly excusable because of the absence of information about contamination with quinocide. After presentation of [3] [7] [8] [17]- [26] , it is not acceptable for serious scientists to publish such data as [28] . The isomers undergo the same derivatization and give the similar UV spectra. It is not possible by these reactions and UV spectroscopic measurements to differentiate the constitutional isomers or to quantify them correctly. Chromatographic or capillary electrophoretic methods must be used [3] [7] [8] [17]- [26] . In publication [28] , the authors were well aware of the presence of isomers in their analytical procedure, because they previously published papers [2] [27] . Publication [28] should be considered as a direct service to the pharmaceutical industry to conceal the fact of the presence of contaminants. Despite the knowledge of the reviewers, editors and editors in chief that this team continually publishes fraudulent papers, the papers were published with the help of their patrons from the pharmaceutical industry. 
Appeal

Discussion
The derivatization reactions and subsequent UV spectrometric quantitative and qualitative analysis require careful checks for the presence of interfering factors and substances. In particular, this is necessary for pharmaceutical products and methods under development. This was not done in paper [28] , even though the authors well knew that primaquine contains its isomer quinocide. There is no doubt about that this publication falsifies facts so as to hide the presence of a toxic substance mixed with the antimalarial drug primaquine. Analytical chromatography must be used in these cases.
Conclusion
No publisher who wishes to be numbered among the recognized, honest, publishers with professional integrity can allow the accommodation of plagiarists and corrupt editors. The only way to avoid double publications, fraudulent presentations and falsifications in science, arts, social life and politics is to keep swindlers out of the important field of public information. We are in 
